An Evaluation of the Cost Effectiveness of Adding Lamivudine to Zidovudine-Containing Regimens in HIV Infection
- 1 January 1999
- journal article
- clinical trial
- Published by Springer Nature in PharmacoEconomics
- Vol. 15 (1), 55-66
- https://doi.org/10.2165/00019053-199915001-00005
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Lamivudine Reduces Healthcare Resource Use when Added to Zidovudine-Containing Regimens in Patients with HIV InfectionPharmacoEconomics, 1999
- The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.1998
- Improved Survival Among HIV-Infected Individuals Following Initiation of Antiretroviral TherapyJAMA, 1998
- Modelling the Potential Economic Impact of Viral Load???Driven Triple Drug Combination Antiretroviral TherapyPharmacoEconomics, 1998
- Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centresAIDS, 1997
- Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.PharmacoEconomics, 1997
- Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial.1997
- Confidence Intervals for Cost-Effectiveness Ratios: A Comparison of Four MethodsHealth Economics, 1997
- On the decision rules of cost-effectiveness analysisJournal of Health Economics, 1993
- Economic Analysis in Randomized Control TrialsMedical Care, 1992